CytomX Therapeutics CTMX
NASDAQ CTMX
$2.42 -0.09 (-3.39%)
As of: Oct 21, 2026 · 3:34 PM EDT

CytomX Therapeutics (CTMX) Short term Debt (2014)

Updated

CytomX Therapeutics' Short term Debt was $1.42 million in Q4 2014.

Analysis

CytomX Therapeutics (CTMX) Short term Debt (2014) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,137.26 Bn 1,105.84 Bn 19.71 Bn
2 Johnson & Johnson 618.12 Bn 536.65 Bn 17.26 Bn
3 AbbVie 503.25 Bn 476.36 Bn 12.70 Bn
4 Merck 368.28 Bn 322.66 Bn 12.21 Bn
5 Novartis Ag 298.45 Bn 262.44 Bn 11.24 Bn
6 Astrazeneca 261.39 Bn 235.08 Bn 12.86 Bn
7 Amgen 237.30 Bn 192.70 Bn 7.24 Bn
8 Gilead Sciences 191.35 Bn 165.55 Bn 6.22 Bn
9 Pfizer 169.92 Bn 116.56 Bn 10.94 Bn
10 CytomX Therapeutics 530.93 Mn -426.74 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2014 1.42 Mn
API Access

CytomX Therapeutics Short term Debt API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=short-term-debt&ticker=CTMX&period=max&api_key=YOUR_API_KEY